“We need to go in a new direction at FDA, and everybody fully supports Secretary Kennedy’s vision to Make America Healthy Again and get back to a more populist and common-sense approach to health in America,” a senior administration official told Axios late Tuesday.
The White House is dropping Dr. Heidi Overton’s nomination to lead the Food and Drug Administration, a White House official confirmed Tuesday, one day before the Senate Health Committee was scheduled to vote on whether to advance her nomination to the full Senate. Axios first reported the decision.
“FDA nominee Heidi Overton lacks the support on the Hill to move forward with her confirmation,” the senior administration official said.
Overton, a physician and deputy director of the White House Domestic Policy Council, was nominated by President Trump in August. To advance out of the 21-member Health, Education, Pensions and Labor Committee, she would have needed 11 votes, meaning she could not afford to lose a single Republican if all Democrats opposed her.
Republican doubts
The move followed weeks of doubts from key Republicans. Sen. Bill Cassidy of Louisiana, the committee’s chairman, had scheduled the vote for Wednesday morning despite struggling to convince wavering GOP members. Before her September confirmation hearing, Cassidy wrote on X that he had “strong concerns” about her nomination, saying her lack of managerial experience left her poorly prepared to lead the agency.
He also said he had “strong concerns” about Overton’s role in the administration’s efforts to change childhood vaccine recommendations, which he called “almost disqualifying.” In a post last week, Cassidy said he remained undecided.
Over the last several months, I have had several frank conversations with both Dr. Overton and Mr. O’Neill about their visions, roles, and the lack of trust that exists due to broken promises and irresponsible decisions from other officials within the Administration. I appreciate…
Sen. Susan Collins of Maine told NBC News last week she was undecided and had “not taken a position,” saying she needed “to get some answers on various things.”
Sen. Lisa Murkowski of Alaska declined last week to say how she’d vote, and during the hearing criticized Overton for not taking a clear position on political pressure surrounding access to mifepristone. Several Republicans, including Murkowski and Sen. Josh Hawley of Missouri, would not say Tuesday how they planned to vote, according to The Washington Sun.
Outside pressure
Overton faced pressure campaigns on multiple fronts. Hawley had been under heavy pressure from Marjorie Dannenfelser, president of SBA Pro-Life America, to oppose Overton unless the administration promised to expedite a thorough review of the abortion pill mifepristone — promises that would have further repelled the panel’s two Republicans who support abortion rights, Murkowski and Collins.
Antiabortion forces had questioned Overton’s commitment to tightening prescribing rules for mifepristone, and she drew criticism from segments of the MAHA movement that saw her as siding with health and agriculture interests.

Signs reading “Say no to Heidi Vaperton for FDA commissioner” appeared around Washington over the weekend, placed by a “private group of citizens who prefer to stay anonymous,” according to group spokesperson Jenny Kay.
Former White House health adviser Calley Means, a close ally of Health Secretary Robert F. Kennedy Jr., had castigated Overton in interviews, saying she helped advance vaping industry interests. Means told The Washington Sun on Tuesday he is not involved in the group behind the signs.
The FDA has been led by acting Commissioner Kyle Diamantas since Dr. Marty Makary resigned in May, in part over the administration’s decision to authorize several fruit-flavored vaping products. The agency is set to finish its safety review of mifepristone in March.
Breaking news: The White House is abandoning the nomination of Heidi Overton to lead the FDA amid growing concerns that she could not be confirmed by the Senate. https://t.co/JWHZ1WjVpd
Republicans have only a narrow window to confirm dozens of Trump administration nominees before Democrats take over Congress next year, and without a clear pick, filling the FDA post before Republicans lose the majority could prove extremely difficult.
More on Heidi Overton
Dr. Heidi Overton’s nomination to lead the Food and Drug Administration was dropped on Tuesday, a White House official confirmed to ABC News. Read more: https://t.co/oobI2rEEGl pic.twitter.com/YPSdHLwlNO
The White House has pulled Dr. Heidi Overton's nomination to lead the FDA in the face of Senate opposition to her candidacy, according to a White House official and two sources familiar with the matter. https://t.co/oxIzXrOSSi pic.twitter.com/6otiBsnX9y
The White House has pulled Dr. Heidi Overton's nomination to lead the FDA in the face of Senate opposition to her candidacy, a White House official confirmed. https://t.co/1bGWGjEke1
The White House said Tuesday it has pulled the nomination of Dr. Heidi Overton to lead the Food and Drug Administration amid growing indications she didn't have the votes needed to win Senate confirmation. https://t.co/nus5y4MTsR